Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2022

View Archived Issues

Identification of sites of metabolic liability for KRM-II-81 and evaluation of a deuterated analogue

Variant in the CTR1 gene causes novel disorder of copper metabolism

MK-6158: sGC stimulator clinical candidate for pulmonary arterial hypertension

Novel nonhallucinogenic DMT analogues as drug candidates for mental health and addiction disorders

Phosphatidylserine is crucial for synaptic pruning in adult-born neurons

New antibacterials identified at Roche

Yale University divulges new oligosaccharyltransferase complex inhibitors

HDAC inhibitors disovered at Chong Kun Dang Pharmaceutical

Dompe Farmaceutici describes new peptides with angiogenic activity

Bayer patents P2X purinoceptor 4 antagonists

Novel USP30 inhibitors as potential anti-Parkinson candidates

Novartis details discovery, preclinical data of novel antimalarial compound INE-963

Sosei Heptares' GLP-1/2 agonist HTL-0030023 shows promising results for treating NAFLD and NASH

Missense variants in DDX39B linked to novel syndrome of global neurodevelopmental delay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...